One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)
Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability. To support the discovery of potent and selective WRN inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to support hit finding and lead optimization efforts targeting WRN. Our panel of services also include high-quality WRN protein production and established X-ray crystallography protocols.
Werner Syndrome Helicase Platform
Related Content
DNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCETargeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular...
VIEW RESOURCE